Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Royalty Pharma plc RPRX

Healthcare Biotechnology
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including... see more

Recent & Breaking News (NDAQ:RPRX)

Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness

PR Newswire January 9, 2023

Royalty Pharma Announces Dividend Increase

GlobeNewswire January 9, 2023

Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9

GlobeNewswire January 4, 2023

Royalty Pharma Announces Expansion of Senior Leadership Team

GlobeNewswire December 15, 2022

Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference

GlobeNewswire November 28, 2022

Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones

GlobeNewswire November 9, 2022

Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones

Business Wire November 9, 2022

Royalty Pharma Reports Third Quarter 2022 Results

GlobeNewswire November 8, 2022

Royalty Pharma to Announce Third Quarter 2022 Financial Results on November 8, 2022

GlobeNewswire October 18, 2022

Royalty Pharma Declares Fourth Quarter 2022 Dividend

GlobeNewswire October 17, 2022

Royalty Pharma Announces Expansion of Leadership Team

GlobeNewswire October 12, 2022

Royalty Pharma Announces R&D Funding Collaboration With Merck

GlobeNewswire October 12, 2022

Royalty Pharma to Present at Upcoming Investor Conferences

GlobeNewswire September 6, 2022

Royalty Pharma Reports Second Quarter 2022 Results

GlobeNewswire August 4, 2022

Royalty Pharma Declares Third Quarter 2022 Dividend

GlobeNewswire July 15, 2022

Royalty Pharma to Announce Second Quarter 2022 Financial Results on August 4, 2022

GlobeNewswire July 14, 2022

Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million

GlobeNewswire July 13, 2022

Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value

PR Newswire July 13, 2022

Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million

GlobeNewswire June 30, 2022

Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma

PR Newswire June 30, 2022